# Clinical Performance Evaluation of the NeuMoDx™ FluA/FluB/RSV/Severe Acute Respiratory Syndrome-CoV-2 Assay

> **NCT05162547** · — · COMPLETED · sponsor: **QIAGEN Gaithersburg, Inc** · enrollment: 2383 (actual)

## Conditions studied

- Respiratory Disease

## Interventions

- **DEVICE:** NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay

## Key facts

- **NCT ID:** NCT05162547
- **Lead sponsor:** QIAGEN Gaithersburg, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-11
- **Primary completion:** 2024-02-07
- **Final completion:** 2024-02-07
- **Target enrollment:** 2383 (ACTUAL)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162547, "Clinical Performance Evaluation of the NeuMoDx™ FluA/FluB/RSV/Severe Acute Respiratory Syndrome-CoV-2 Assay". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05162547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*